HAART during pregnancy and during breastfeeding among HIV-infected women in the developing world: Has the time come?

AIDS

Volumn 23, Issue 18, 2009, Pages 2473-2477

  Bulterys, Marc ^a,b   Wilfert, Catherine M ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MATERNAL CARE; NOTE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RWANDA;

EID: 72949108030     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333866c     Document Type: Note

References (61)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, District of Columbia, USA: Department of Health and Human Services; 2008. http://aidsinfo.nih.gov. [Accessed 23 July 2009]
2. Uy J, Armon C, Buchacz K, Wood K, Brooks JT, and the HOPS investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009; 51:450-453.
3. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
4. Sax PE, Baden LR. When to start antiretroviral therapy: ready when you are? N Engl J Med 2009; 360:1897-1899.
5. Sterne JA, May M, Cotagliola D, de WolfF, Phillips AN, Harris R, et al. When To Start Consortium. Timing of initiation of anti-retroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
6. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetrical outcomes and few maternal toxi-cities are associated with antiretroviral therapy including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38:449-473.
7. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach; 2006. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf [Accessed 8 August 2009]
8. Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 2009; 23:2425-2430.
9. Food and Drug Administration. FDA public health advisory for nevirapine (viramune); 2005. http://www.fda.gov/cder/drug/advisory/nevirapine.htm.
10. Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, et al. Maternal hepatotoxicity with nevirapine as partof combination antiretroviral therapy in pregnancy. HIV Med 2006; 7:255-260.
11. Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44:371-376.
12. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36:772-776.
13. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakaiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
14. Peltier CA, Ndayisaba GF, Lepage P, van Griensven J, Leroy V, Omes C, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009; 23: 2415-2423.
15. Thomas T, Masaba R, Ndivo R, Zeh C, Borkowf C, Thigpen M, et al. PMTCT of HIV-1 among breastfeeding mothers using HAART: the Kisumu Breastfeeding Study, Kisumu, Kenya, 2003-2007 [abstract #45aLB]. In: Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts, USA.
16. Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G, et al. A study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load. J Acquir Immune Defic Syndr 2008; 47:647-649.
17. Marazzi MC, Nielsen-Saines K, Buonomo E, Scarcella P, Germano P, Majid NA, et al. Increased infant human immunodeficiency virus type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antire-troviral therapy during breast-feeding. Pediatr Infect Dis J 2009; 28:483-487.
18. De Vincenzi I, for the Kesho Bora Study Group. HIV-free survival at 12 months among children born to HIV-infected women receiving antiretrovirals from 34 to 36 weeks of pregnancy [abstract #638]. In: Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts, USA.
19. De Vincenzi I, for the Kesho Bora Study Group. Triple-antire-troviral prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1: the Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya and South Africa [abstract #LBPeC01]. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 2009; Cape Town, South Africa.
20. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Medicine 2007; 4:e257.
21. Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr 2009; 21:83-93.
22. Wilfert CM, Fowler MG. Balancing maternal and infant benefits and the consequences of breast-feeding in the developing world during the era of HIV infection. J Infect Dis 2007; 195:165-167.
23. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis 2006; 6:726-732.
24. Van de Perre P, Lepage P, Homsy J, Dabis F. Mother-to-infant transmission of human immunodeficiency virus by breast milk: presumed innocent or presumed guilty? Clin Infect Dis 1992; 15:502-507.
25. Mofenson LM. Antiretroviral prophylaxis to reduce breast milk transmission of HIV type 1: new data but still questions. J Acquir Immune Defic Syndr 2008; 48:237-240.
26. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector-progress report; 2008. http://www.who.int/hiv/pub/towards-universal- access-report-2008.pdf. [Accessed 31 July 2009]
27. Mach O, Lu L, Creek T, Bowen A, Arvelo W, Smit M, et al. Population-based study of a widespread outbreak of diarrhea associated with increased mortality and malnutrition in Botswana, January-March 2006. Am J Trop Med Hyg 2009; 80: 812-818.
28. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Hey-mann SJ, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial-the Mashi Study. JAMA 2006; 296:794-805.
29. Becquet R, Becquet L, Ekouevi DK, Viho I, Sakarovitch C, Fassinou P, et al. Two-year morbidity-mortality and alternatives to prolonged breastfeeding among children born to HIV-infected mothers in Co?te d'Ivoire. PLoS Med 2007; 4:e17.
30. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and childhood mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet 2000; 355:451-455.
31. Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Mwiya M, et al. Effects of early, abrupt weaning on HIV-free survivalofchildreninZambia.N Engl J Med2008; 359:130-141.
32. Rollins NC, BecquetR, Bland RM, CoutsoudisA, Coovadia HM, Newell ML. Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes. AIDS 2008; 22:2349-2359.
33. Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY, Coovadia HM, et al. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15:379-387.
34. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107-1116.
35. Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005; 19:699-708.
36. Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-129.
37. Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, et al. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials. Lancet 2008; 372:300-313.
38. Chasela C, Hudgens M, Jamieson D, Kayira D, Hosseinipour M, Ahmed Y, et al. Both maternal HAART and daily infant nevir-apine are effective in reducing HIV-1 transmission during breastfeeding in a randomized trial in Malawi: 28 week results of the Breastfeeding, Antiretroviral and Nutrition (BAN) Study [abstract #WeLBC103]. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 2009; Cape Town, South Africa.
39. Kilewo C, Karlsson K, MassaweA, Lyamuya E, Swai A, Mhalu F, et al. Prevention of mother to child transmission of HIV-1 through breastfeeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the MITRA study. J Acquir Immune Defic Syndr 2008; 48:315-323.
40. Abrams EJ, Myer L, Rosenfield A, El-Sadr WM. Prevention of mother-to-child transmission services as a gateway to family-based HIV care and treatment in resource-limited settings: rationale and international experience. Am J Obstet Gynecol 2007; 197 (Suppl 3):S101-S106.
41. Dao H, Mofenson LM, Ekpini R, Gilks CF, Barnhart M, Bolu O, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 2007; 197 (Suppl 3):S42-S55.
42. Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727.
43. Bulterys M, Weidle PJ, Abrams EJ, Fowler MG. Combination antiretroviral therapy in African nursing mothers and drug exposure in their infants: new pharmacokinetic and virologic findings. J Infect Dis 2005; 192:709-712.
44. Mirochnick M, Thomas T, Capparelli E, Zeh C, Holland D, Masaba R, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrobiol Agents Chemother 2009; 53:1170-1176.
45. Ford N, Mills E, Calmy A. Rationing antiretroviral therapy in Africa: treating too few, too late. N Engl J Med 2009; 360:1808-1810.
46. ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA). Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870-879.
47. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Co?te d'Ivoire. N Engl J Med 2006; 355:1141-1153.
48. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
49. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behum-biize P, etal. MortalityinHIV-infectedUgandanadults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008; 371:752-759.
50. Lowrance DW, Makombe S, Harries AD, Shiraishi RW, Hoch-gesang M, Aberle-Grasse J, et al. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr 2008; 49:287-293.
51. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
52. Bulterys M, Vermund SH, Chen RY, Ou CY. A public health approach to rapid scale-up of free antiretroviral treatment in China: an ounce of prevention is worth a pound of cure. Chin Med J 2009; 122:1352-1355.
53. De Cock KM, Gilks CF, Lo YR, Guerma T. Can antiretroviral therapy eliminate HIV transmission? Lancet 2009; 373:7-9.
54. Lebon A, Bland RM, Rollins NC, Coutsoudis A, Coovadia H, Newell M-L. CD4 counts of HIV-infected pregnant women and their infected children: implications for PMTCT and treatment programmes. Trop Med Int Health 2007; 12:1472-1474.
55. Ammann AJ. Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies (editorial). J Acquir Immune Defic Syndr 2009; 51:509-512.
56. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of preterm delivery. N Engl J Med 2002; 346:1863-1870.
57. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-1026.
58. Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9:6-13.
59. Tuomala RE, Yawetz S. Protease inhibitor use during pregnancy: is there an obstetrical risk? J Infect Dis 2006; 193:1191-1194.
60. Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, et al. Postnatal HIV-1 transmission after cessation of extended prophylaxis and effect of maternal HAART. J Infect Dis (in press).
61. Reithinger R, Meggazzini K, Durako SJ, Harris DR, Vermund SH. Monitoring and evaluation of programmes to prevent mother-to-child transmission of HIV in Africa. Br Med J 2007; 334:1143-1146.